Transforming the management of cancer with personalized testing
Signatera is a highly sensitive and personalized molecular residual disease assay (MRD) using circulating tumor DNA (ctDNA), custom designed for each patient to help identify relapse earlier than standard of care tools
Knowing earlier matters
Each person’s cancer is as unique as their fingerprint. Signatera is a MRD blood test that is personalized to each patient’s set of tumor mutations and can identify earlier than traditional tools if cancer is still present. Knowing this information can help you have a more informed discussion with your doctor regarding your treatment journey.
How Signatera helps patients through their treatment
Living scan to scan can sometimes create anxiety for patients. The question of relapse looms in the back of their mind: Did the treatment work? Is the cancer coming back?
Through shared decision making, patients can work closely with their care team to incorporate Signatera into their treatment plan to provide additional information for confident decision making. Listen to Brooks Bell tell her story of how she achieved peace of mind between scans using Signatera.
Finding reassurance with Signatera
After JoAnn was diagnosed with lung cancer, she learned how Signatera could help her doctor detect potential disease progression ahead of scans. As part of her cancer monitoring plan, she received Signatera testing at regular intervals, helping her and her doctor make critical decisions. Learn how Signatera helped JoAnn and her family stay confident and positive throughout her treatment journey.
Living with lung cancer